CMS Open Payments · Program Year 2024
LumiraDx, Inc.
LumiraDx, Inc. reported $600.00 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 2 transactions.
- $600.00
- All-tracks total
- 2
- Transactions
- 2
- Recipients
- #1872
- of 1,925 companies
LumiraDx, Inc. reported $600.00 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #1872 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $600.00, averaging $300.00 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer lumiradx-inc LumiraDx, Inc.
$600.00 · #1872/1,925 · 0.0% industry · PY2024
- TOT $600.00
- RANK #1872
- SHARE 0.0%
- TXN 2
- RCP 2
- CAT 1
- GEN $600.00
- TOP1 50.0%
- PY 2024
Volume peers
Nearest volume peer: Pixee Medical Inc. ($601.00)
LumiraDx, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for LumiraDx, Inc.
LumiraDx, Inc. ranks #1872 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $600.00 across 2 transactions to 2 physicians and teaching hospitals - $300.00 per transaction and $300.00 per recipient on average.
Of the 1 general-payment categories charted below, "Consulting Fee" is the largest at $600.00 across 2 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads LumiraDx, Inc.'s 1-category general-payment breakdown at $600.00, 100.0% of the reported total.
How LumiraDx, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $600.00 | 2 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $600.00 (100.0%) of $600.00 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for LumiraDx, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Christopher Defilippi
$300.00 across 1 reported transactions
- 2
Allan Jaffe
$300.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as LumiraDx, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about LumiraDx, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with LumiraDx, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vantage Technology LLC
Cook Biotech Incorporated
R-Pharm US LLC
curasan, Inc.
Nurami Medical Ltd
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.